A brief study entitled “Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease” identified orexin, a protein that triggers the brain to wake after sleeping, as a potential new factor in Alzheimer’s disease. The study was published in November issue of The Journal of Experimental Medicine.
Another investigational drug trial for the treatment of Alzheimer’s is set to release key findings within the next few months. Neurotrope, Inc. recently announced the closure of their Phase 2a clinical trial of Bryostatin-1, as the last patient enrolled in the study was administered the drug. The trial was conducted under an Investigational New…
The Texas A&M Health Science Center College of Medicine recently launched a new initiative against Alzheimer’s Disease that aims to encourage the use of the Texas Alzheimer’s Research and Care Consortium’s (TARCC) large patient cohort. The TARCC Investigator Grant Program will be awarding a total of five inaugural grants worth $50,000 each, and two grants…
In a review study entitled “Vascular risk factors and Alzheimer’s disease,” the authors perform a comprehensive retrospective of a series of studies linking Alzheimer’s disease and vascular factors. The review was published in the BMC Medicine journal. Neurodegenerative decline, characterized by dementia, is currently estimated to affect…
Home Instead Senior Care (Home Instead SC) recently joined healthcare leaders from G7 governments for a general discussion regarding the progress made in community-based patient care initiatives and education as part of the Global Action against Dementia Legacy program. Home Instead’s president Jeff Huber and Duskin Company Home Instead Division Manager …
Researchers at Temple University blocked the thromboxane brain cell receptor, stopping oxidative stress in an Alzheimer’s mouse model, and preventing key symptoms of the disease. In Alzheimer’s disease two pathological proteins accumulate in the brain: beta-amyloid protein and hyper-phosphorylated tau. Both are thought to wreak havoc by causing progressive…
In a new study entitled “Metabotropic P2Y1 receptor signaling mediates astrocytic hyperactivity in vivo in an Alzheimer’s disease mouse model” published in Nature Communications, Andrea Delekate and colleagues examined the astrocytic network underlying pathways that may be implicated in Alzheimer’s disease (AD), and provide solid evidence for…
Biopharmaceutical company Anavex Life Sciences Corp. recently presented encouraging results from their phase 1 clinical trial, a study testing the company’s lead investigational oral treatment for Alzheimer’s disease, Anavex 2-73, at CNS Summit 2014 in Boca Raton, Florida. After assessing the drug’s safety and effectiveness, the medication…
A recent review from Schichun Tu and colleagues entitled “Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease” was published this week in the journal Molecular Neurodegeneration. The aim of the study was to discuss the state of current evidence suggesting that the synaptic loss found in…
Cognition Therapeutics Inc. announced the discovery of a new drug target in the brain that plays a role in the development of Alzheimer’s disease, and their investigation of new drug candidates to reverse the memory loss associated with Alzheimer’s. The two studies were entitled “Alzheimer’s therapeutics targeting Amyloid beta 1-42…
Get regular updates to your inbox.